Psychopharmacology

Latest News

Brexpiprazole + Sertraline Combination for PTSD Submitted for sNDA Review
Brexpiprazole + Sertraline Combination for PTSD Submitted for sNDA Review

April 12th 2024

A supplemental new drug application was submitted for the combination of brexpiprazole and sertraline in the treatment of PTSD in adults.

From a groundbreaking FDA approval to the hidden toll of COVID-19, here are highlights from the week in Psychiatric Times.
The Week in Review: April 1-5

April 6th 2024

This alters the course of developer Eisai's regulatory submission plans for lecanemab in the treatment of early Alzheimer disease.
FDA: Specific Fast Track Designation for Subcutaneous Formulation of Leqembi for Alzheimer Disease Needed for Rolling Review

April 3rd 2024

“The selectivity of NBI-1070770 for the NMDA NR2B receptor may benefit patients with moderate to severe depression.”
First Patient Dosed in Phase 2 Clinical Trial of NBI-1070770 for MDD

April 3rd 2024

The atypical antipsychotic was approved for the acute treatment of schizophrenia in 2009.
FDA Approves Fanapt for Mixed, Manic Episodes Associated With Bipolar I Disorder

April 2nd 2024

Video Interviews
Podcasts
Latest CME Events & Activities

The Expanding Role of Fluid Biomarkers in the Diagnosis and Management of Patients With Alzheimer Disease

View More

Clinical Consultations™: Considerations for Customizing Care Plans for Patients with Parkinson Disease Psychosis

View More

Expert Illustrations & Commentaries™: Visualizing New Therapeutic Targets in Schizophrenia

View More

Advances In™ Schizophrenia: Expanding the Therapeutic Landscape

View More

Southern California Psychiatry Conference

September 13-14, 2024

Register Now!

Updates on New and Emerging Therapies to Improve Outcomes for Patients With Major Depressive Disorder

View More

5th Annual International Congress on the Future of Neurology®

View More

2023 Annual Psychiatric Times™ World CME Conference

View More

Clinical Consultations™: Managing Depressive Episodes in Patients with Bipolar Disorder Type II

View More

Patient, Provider, and Caregiver Connection™: Exploring Unmet Needs In Postpartum Depression – Making the Case for Early Detection and Novel Treatments

View More

Medical Crossfire®: Understanding the Advances in Bipolar Disease Treatment—A Comprehensive Look at Treatment Selection Strategies

View More

'REEL’ Time Patient Counseling: The Diagnostic and Treatment Journey for Patients With Bipolar Disorder Type II – From Primary to Specialty Care

View More

More Than ‘Blue’ After Birth: Managing Diagnosis and Treatment of Post-Partum Depression

View More

Patient, Provider & Caregiver Connection™: Reducing the Burden of Parkinson Disease Psychosis with Personalized Management Plans

View More

More News

© 2024 MJH Life Sciences

All rights reserved.